Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study
- Johan Sieborg*
- , Julia-Tatjana Maul
- , Jashin J Wu
- , Nikolai Nguyen Loft
- , Lone Skov
- , Lars Erik Bryld
- , Mads Kirchheiner Rasmussen
- , Tomas Norman Dam
- , Trine Bertelsen
- , Kawa Khaled Ajgeiy
- , Simon Francis Thomsen
- , Jacob P Thyssen
- , Alexander Egeberg
- , David Thein
*Corresponding author af dette arbejde
Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review